Atopic dermatitis (AD) and psoriasis (PSO) are the most common chronic inflammatory dermatosis that manifest chronic courses and require long-term treatment. [1][2][3] Treatments such as topical glucocorticoids (TGCs), immunosuppressive drugs and phototherapy have been used for both diseases. Among them, TGCs have been commonly used to treat mild-to-moderate cases of AD and PSO. [4][5][6][7][8][9] Although corticosteroids are primarily produced in the adrenal gland, they can also be produced in extra-adrenal tissues, such as those of the immune system, and the skin, brain and intestine. 10 In the skin, glucocorticoid synthesis begins with cholesterol, and steroidogenesis is regulated in a complex fashion. 11,12 Although TGCs can effectively treat AD and PSO, cutaneous adverse effects of TGCs, including atrophy, striae, rosacea, perioral dermatitis, acne and purpura, typically occur with prolonged use. 13,14 Skin atrophy